Neurocrine Biosciences NBIX
Neurocrine Biosciences (Nasdaq: NBIX) is a CNS/neurology/psychiatry drug developer. Its lead program, direclidine in schizophrenia, is in Phase 3 for schizophrenia.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INGREZZA (valbenazine) | tardive dyskinesia; chorea in Huntington's disease | small molecule | Approved |
| CRENESSITY (crinecerfont) | classic congenital adrenal hyperplasia | small molecule | Approved |
| VYKAT (diazoxide choline) XR | hyperphagia in Prader-Willi syndrome | small molecule | Approved |
| direclidine | schizophrenia | small molecule | Phase 3 |
| osavampator | major depressive disorder | small molecule | Phase 3 |
| NBI-1117567 | Alzheimer's cognition | small molecule | Phase 3 |
| NBI-1117570 | schizophrenia | small molecule | Phase 2 |
| crinecerfont | CAH in children aged 3 months to under 4 years | small molecule | Phase 2 |
| NBI-1065890 | tardive dyskinesia | small molecule | Phase 2 |
| NBIP-1968 | obesity | peptide | Phase 1 |
| NBIP-2118 | obesity | peptide | Phase 1 |
| NBIM-1008 | rheumatoid arthritis | unclear | Phase 1 |
Recent results and decisions
- Nov 2, 2026started Neurocrine announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist for obesity.
Announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity.
Filing - Mar 31, 2026started Neurocrine initiated a Phase 1 study in Q1 2026 of NBIP-2118, a CRF2 peptide agonist.
This follows the Q1 2026 initiation of a Phase 1 first-in-human clinical study of NBIP-'2118, a potential first-in-class CRF2 peptide agonist.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.